Standard Contracts
THIS AGREEMENT effective as of the 29th day of June, 1983, by and between Dr. Stanislaw R. Burzynski ("Dr. Burzynski") having an address at 5 Concord CR, Houston Texas, and Burzynski Research Institute, Inc. (the "Company") having its principal place...Licensing Agreement • November 25th, 1997 • Burzynski Research Institute Inc • Nevada
Contract Type FiledNovember 25th, 1997 Company Jurisdiction
AMENDED LICENSE AGREEMENT THIS WRITTEN AGREEMENT amends and supersedes that certain License Agreement dated June 29, 1983, whereunder Dr. Stanislaw R. Burzynski ("Dr. Burzynski") granted a license to Burzynski Research Institute, Inc. (herein the...License Agreement • November 25th, 1997 • Burzynski Research Institute Inc • Delaware
Contract Type FiledNovember 25th, 1997 Company Jurisdiction
ROYALTY AGREEMENTRoyalty Agreement • November 25th, 1997 • Burzynski Research Institute Inc
Contract Type FiledNovember 25th, 1997 Company
FIRST AMENDMENT TO RESEARCH FUNDING AGREEMENT This First Amendment To Research Funding Agreement (the "Amendment"), effective as of March 1, 2001, is entered into by and between Stanislaw R. Burzynski, M.D., PhD. ("Dr. Burzynski") and Burzynski...Research Funding Agreement • May 2nd, 2001 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances • Texas
Contract Type FiledMay 2nd, 2001 Company Industry Jurisdiction
SECOND AMENDMENT TO THE RESEARCH FUNDING AGREEMENTResearch Funding Agreement • June 1st, 2004 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
Contract Type FiledJune 1st, 2004 Company IndustryThis Second Amendment to the Research Funding Agreement is dated as of February 29, 2004. On or about March 1, 2001, Dr. Stanislaw R. Burzynski and the Burzynski Research Institute, Inc. (BRI) entered into a First Amendment to the Research Funding Agreement, under which funding agreement, inter alia, Dr. Burzynski agreed to fund the research undertaken by BRI.
AMENDED AND RESTATED ROYALTY AGREEMENTRoyalty Agreement • May 22nd, 2023 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
Contract Type FiledMay 22nd, 2023 Company IndustryTHIS AMENDED AND RESTATED AGREEMENT (the "Agreement") made and entered into May 22, 2023 by and between STANISLAW R. BURZYNSKI, M.D., Ph.D. ("BURZYNSKI") with offices at 9432 Katy Freeway, Suite 200, Houston, Texas 77055 and Burzynski Research Institute, Inc. (the "Company"), a Delaware corporation with offices located at 9432 Katy Freeway, Suite 200, Houston, Texas 77055.
Marketing and Consulting AgreementMarketing and Consulting Agreement • July 6th, 2012 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances • Texas
Contract Type FiledJuly 6th, 2012 Company Industry JurisdictionThis Marketing and Consulting Agreement (“Agreement”) is entered into this 5th day of July, 2012, by and among Burzynski Research Institute, Inc., a Delaware corporation (including its successors or permitted assigns, “BRI”), a Delaware corporation, Worldwide Medical Consultants, Inc., a Delaware corporation (“Consultant”), and CARIGEN, LTD, a Cayman Island company (including its successors or permitted assigns, “SRB”).
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • October 15th, 2003 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2003 Company IndustryTHIS AGREEMENT effective as of March 1,1997, by and between Stanislaw R. Burzynski, M.D. Ph.D (hereinafter “SRB”) having his principal place of business at 12000 Richmond Avenue, Houston, Texas and the Burzynski Research Institute, Inc., a Delaware Corporation (“BRI”) having its principal place of business at 12000 Richmond Avenue, Houston Texas hereby agree as follows:
THIRD AMENDMENT TO THE RESEARCH FUNDING AGREEMENTResearch Funding Agreement • May 29th, 2007 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
Contract Type FiledMay 29th, 2007 Company IndustryOn or about February 29, 2004, Dr. Stanislaw R. Burzynski and the Burzynski Research Institute, Inc. (BRI) entered into a Second Amendment to the Research Funding Agreement, under which funding agreement, inter alia, Dr. Burzynski agreed to fund the research undertaken by BRI.
AMENDED AND RESTATED RESEARCH FUNDING AGREEMENTResearch Funding Agreement • May 22nd, 2023 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
Contract Type FiledMay 22nd, 2023 Company IndustryTHIS AMENDED AND RESTATED AGREEMENT (the "Agreement”) effective as of May 22, 2023, by and between Stanislaw R. Burzynski, M.D. Ph.D (hereinafter "SRB") with offices at 9432 Katy Freeway, Suite 200, Houston, Texas 77055 and Burzynski Research Institute, Inc. (the "Company"), a Delaware corporation with offices located at 9432 Katy Freeway, Suite 200, Houston, Texas 77055:
LICENSE AGREEMENTLicense Agreement • May 22nd, 2023 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
Contract Type FiledMay 22nd, 2023 Company IndustryLICENSE AGREEMENT dated May 22, 2023, by and between Dr. Stanislaw R. Burzynski ("Dr. Burzynski") with offices at 9432 Katy Freeway, Suite 200, Houston, Texas 77055 and Burzynski Research Institute, Inc. (the "Company"), a Delaware corporation with offices located at 9432 Katy Freeway, Suite 200, Houston, Texas 77055.